Palo Alto, California-based SyncThink, a developer of eye-tracking technology products, has named Laura Yecies as CEO. SyncThink’s backers include Quadrant Management Inc.
Palo Alto, CA–April 4, 2018—SyncThink, a world leader in neurotechnology and brain health analytics with foundational IP in eye-tracking, announces the appointment of Laura Yecies as its new CEO.
A two-time successful CEO, Harvard MBA, and Silicon Valley veteran, SyncThink gains a visionary leader in Yecies. In her new role, she will work closely with the Board of Directors and executive team to set the strategy, build and execute the operational plan, as well as drive the Company’s growth.
“SyncThink is at the forefront of one of the most important health issues we are facing – protecting and optimizing our brain health – our fundamental intellectual and emotional identities. I am thrilled to be joining the SyncThink team to help bring our innovative technology to a broader audience,” said Yecies. “Brain health has been called America’s next Moonshot for good reason – it is the least understood human organ and medical interventions are tricky. Technologies such as EYE-SYNC afford the opportunity to more accurately and closely monitor brain health and intervene early to protect and improve it”.
This appointment comes at a breakout time for SyncThink. The Company recently closed a 3.5M funding round, was granted another patent by the U.S. Patent and Trade Office and added NFL Tight End Coby Fleener to its Athlete Advisory Board. In addition, there were announcements on the adoption of its technology by the Golden State Warriors, University of Texas, Iowa State University, the Pac-12 Conference, and more.
“I would like to thank Ernie Santin, our departing CEO, for his tireless efforts in leading the company and positioning it for success,” said Dr. Jamshid Ghajar, Chairman of the Board, Chief Scientific Adviser and Founder of SyncThink. “Laura Yecies brings a wealth of experience in technology and healthcare. We are fortunate to have such an accomplished executive to lead our team.”
SyncThink continues to focus on the applications of its EYE-SYNC device to bring objective eye-tracking measurements and brain health analytics on and off the field. The SyncThink platform is the first comprehensive and objective assessment tool that features dynamic visual attention, cognitive and vestibular/balance assessments that examine the full spectrum of brain health, rapidly, reliably and accurately in a VR headset.
About SyncThink: SyncThink develops revolutionary eye-tracking technology analytics, now in VR headsets, that give medical professionals objective metrics for visual attention and dynamic orientation. Based on 15 years of research and 12 granted patents, SyncThink’s first product, EYE-SYNC, is a 60-second, objective sideline assessment that uses eye tracking to evaluate for ocular motor impairments and vestibular balance dysfunction – the two most common and serious components of concussion. FDA-cleared for detecting eye-tracking impairment, EYE-SYNC is used by leading university athletic departments and medical clinics, from Stanford University to Massachusetts General Hospital, EYE-SYNC is transforming brain health assessment, recovery, and monitoring. www.syncthink.com